Lv1
36 积分 2023-08-29 加入
IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells
3天前
已完结
The Nonclinical Safety Assessment of a Novel Anti-CEACAM5 Antibody Exatecan Conjugate Predicts a Low Risk for Interstitial Lung Disease (ILD) in Patients—The Putative Mechanism Behind ILD
10天前
已完结
A distinct priming phase regulates CD8 T cell immunity by orchestrating paracrine IL-2 signals
15天前
已完结
Potentiating adoptive cell therapy using synthetic IL-9 receptors
26天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
1个月前
已完结
Biology and therapeutic targeting of vascular endothelial growth factor A
1个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
1个月前
已完结
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
1个月前
已完结
皖公网安备34019202002308
